Lin-28 Inhibition for miRNA Processing Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate microRNA biogenesis, particularly the processing of pri-miRNA to mature miRNA, which is crucial for cancer treatment due to the involvement of Lin-28 in blocking this process and maintaining cancer stem cells.
Innovation Solution
Inhibiting or activating Lin-28 activity to modulate miRNA biogenesis, either by inhibiting Lin-28 to increase tumor suppressor miRNAs like let-7 or activating it to decrease oncogenic miRNAs, using agents such as siRNA, antibodies, or nucleic acid molecules to target Lin-28 and its variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Lin-28 is active, then cancer stem cells are maintained and miRNA processing is blocked, but tumor suppressor miRNAs cannot be produced effectively
Solution Approach 1:
The patent extracts and targets Lin-28 protein specifically to remove its inhibitory function on miRNA processing. By using antibodies or other targeting agents against Lin-28, the invention separates the harmful effect (Lin-28 blocking miRNA processing) from the beneficial outcome (production of tumor suppressor miRNAs), thereby resolving the contradiction between maintaining cancer stem cells and producing tumor suppressor miRNAs.
Solution Approach 2:
The patent converts the harmful activity of Lin-28 (which blocks miRNA processing and maintains cancer stem cells) into a beneficial therapeutic target. By developing inhibitors against Lin-28, the invention transforms this harmful factor into a treatable condition, enabling the restoration of normal miRNA processing and the production of tumor suppressor miRNAs that were previously blocked.
2Stability of the object's composition
If Lin-28 inhibits miRNA processing, then cancer stem cells are maintained, but miRNA biogenesis is blocked
Solution Approach 1:
The invention extracts and removes Lin-28 protein from the cellular environment through targeted inhibition. This extraction eliminates the block on miRNA biogenesis while allowing cancer stem cells to lose their self-renewing capability, thereby resolving the contradiction between maintaining stem cell stability and enabling miRNA production.
Solution Approach 2:
The patent introduces intermediary substances (such as antibodies or small molecule inhibitors) that mediate the interaction between therapeutic agents and Lin-28. These intermediaries bind to Lin-28 and prevent its inhibitory function on miRNA processing, thereby restoring miRNA biogenesis without directly affecting cancer stem cell structure.
3Reliability
If tumor suppressor miRNAs are increased, then cancer treatment efficacy improves, but current methods cannot effectively regulate miRNA biogenesis
Solution Approach 1:
The patent extracts the regulatory function from complex cellular processes and focuses it on a single target: Lin-28 protein. By removing Lin-28 through targeted inhibition, the invention simplifies the regulation of miRNA biogenesis and enables effective production of tumor suppressor miRNAs, thereby improving cancer treatment efficacy while making the process more controllable.
Solution Approach 2:
The invention changes the key parameter of Lin-28 activity (from active to inhibited state) to regulate miRNA biogenesis. This parameter change enables the cellular machinery to produce tumor suppressor miRNAs effectively, improving both treatment efficacy and the controllability of the process through well-defined molecular targets.
Data Source
AI summary
The present invention relates generally to methods to regulate microRNA (miRNA) biogenesis, in particular the regulation of the processing of pri-miRNA to mature miRNA by Lin-28 and/or variants such as Lin28B. In particular, the present invention relates to methods and compositions comprising at least one agent which inhibits Lin-28 function or activity and/or expression to increase the processing of pri-mRNA to mature miRNA. More specifically, one aspect of the invention is directed to treating and/or preventing cancer in a subject by administering an agent that inhibits Lin-28 activity or expression to a subject, preferably a human subject.